UnknownNot applicableNCT04488653

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

Studying NON RARE IN EUROPE: Metabolic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Les Derives Resiniques et Terpeniques
Principal Investigator
David Crowley, MD
KGK Science Inc.
Intervention
Oligopin®(dietary_supplement)
Enrollment
40 target
Eligibility
18-55 years · All sexes
Timeline
20202022

Study locations (1)

Collaborators

KGK Science Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04488653 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Metabolic syndrome

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Metabolic syndrome

← Back to all trials